Shuttle Pharmaceuticals Holdings, Inc. (SHPH) Form 10-Q — Sep 24, 2026
Shuttle Pharmaceuticals (SHPH) reported zero revenue and a $5.3 million net loss for the six months ended June 30, 2026, with only $90,238 in cash and a $3.1 million working capital deficit. Management states existing resources are not sufficient to fund operations through the next twelve months, and the financial statements carry substantial doubt going-concern language. The company has radically transformed during the period: it acquired the Molecule.ai AI drug discovery platform, wound down Ropidoxuridine clinical trials, and completed a merger with United Dogecoin, a Dogecoin miner pivoting to AI/HPC digital infrastructure.
Key figures
- Revenue
- 0
- Guidance
- Management plans a significant near-term capital raise targeting $120 million to $150 million
- Total Debt
- 3628859
- Total Assets
- 22811038
- Cash Position
- 90238
- Shares Outstanding
- 4764696
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.